Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 3Carcinoma, Squamous Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Mycosis Fungoides 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Merkel Cell 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 30Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × talimogene laherparepvec × Clear all
NCT03597009 2021-04-20

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
1 enrolled 12 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡